The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.
about
Cognitive enhancers for the treatment of ADHDThe use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorderAlpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD responsePharmacological treatment of PTSD - established and new approachesAlpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animalsAdrenergic pharmacology and cognition: focus on the prefrontal cortexMethylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.Neuromodulator and Emotion Biomarker for Stress Induced Mental DisordersRole of Prefrontal Persistent Activity in Working MemoryDendritic spine pathology in schizophreniaMolecular aspects of age-related cognitive decline: the role of GABA signalingTargeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive DisordersA computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque.A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced ObesityModulators in concert for cognition: modulator interactions in the prefrontal cortexThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Regional differences in cerebral perfusion associated with the alpha-2A-adrenergic receptor genotypes in attention deficit hyperactivity disorderGuanfacine modulates the emotional biasing of amygdala-prefrontal connectivity for cognitive controlPersistent neural activity in the prefrontal cortex: a mechanism by which BDNF regulates working memory?Alterations in the cholinergic system of brain stem neurons in a mouse model of Rett syndromePrefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions.A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessationPharmacological enhancement of memory and executive functioning in laboratory animals.Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.Catecholamine influences on dorsolateral prefrontal cortical networks.Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individualsEffects of α-2A adrenergic receptor agonist on time and risk preference in primatesNoradrenergic dysfunction in Alzheimer's disease.Guanfacine for the treatment of cognitive disorders: a century of discoveries at YaleExperimental strategies for investigating psychostimulant drug actions and prefrontal cortical function in ADHD and related attention disorders.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Noradrenergic control of error perseveration in medial prefrontal cortex.Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control.The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain.The ageing cortical synapse: hallmarks and implications for cognitive declineOnce-daily treatment of ADHD with guanfacine: patient implications.Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.
P2860
Q22251235-692B9071-4229-416F-82E7-01603E1EE026Q24629736-46FE8427-7A5D-4917-84E0-7E30D974A829Q24630396-14AC7D7B-33F0-4960-BCE8-67CA0FE4125DQ24633256-D49421A0-7BBB-43DC-8AA6-4B1B52A13E53Q24682060-563C99F7-32FB-4BB7-89E9-B58C6E344F0EQ24684217-B7182E2C-F623-41F9-98BA-C4715DFFA748Q24810310-2E5A961A-9D6A-4F3C-BB69-415B3931832EQ26751174-15F6ED3B-5825-444F-8DD8-6D7D26BADDA2Q26771523-74264223-5B13-4F50-A245-9CADB203FF0DQ26991935-6E3E7E6D-85EC-4699-98B0-30C32FD17734Q27021454-8A205240-5BB7-465B-8646-37E6D8832477Q28076907-19FB2C0D-E63F-42EC-B913-D590396468D5Q28468318-96F75202-1FA9-4CFE-81AF-E0619C963E67Q28550518-DE003864-B7D2-42CB-980A-8080842E2C6BQ30493218-8B7DC429-50D1-4DFF-8435-5BFEE2821BD3Q33598487-7152E0A1-F0D8-4FDE-A939-94FE4868CCFBQ34084306-4C5BFA38-DCD3-4D9C-ADB2-0D1F2455C736Q34098235-A1FD6278-F4DA-43A1-92F7-577AEC74000EQ34179519-421D8C45-4582-41E5-9BCE-1B4CD24F344BQ34201031-9104A0FD-AD07-4F85-AFB2-6FBBFE5E5F99Q34424490-FC6C8205-155C-4B5A-80F2-53C107F10F60Q34454236-6EAC997B-9BC9-4A67-99E4-AD4E7CC1A786Q34661221-572006BB-DE91-49EF-8E41-44CEF8EB9513Q34677931-04768281-1A5A-43AE-BA80-DCE6F9D1E86EQ35028276-03047984-BCDD-4681-9729-70DE550895D0Q35120282-05E6628E-A542-43BF-BB9C-B51962EA331BQ35132548-D4204985-6416-42A4-9C18-6678F409EADFQ35226150-BF797F54-FB90-401C-B15F-A7B691974AC2Q35608560-C4CD1E37-29AB-4ED2-8702-EF835AFCAACAQ35721180-7438AABC-E556-40E4-9008-17119EC6477AQ35749478-AD6161A9-165D-4575-AE3A-40722BB23606Q35855475-BC547595-087A-4908-B3B5-9F6BC8A518D8Q36445410-C2AF627D-EC0A-4969-862B-8AECC7E9CFECQ36446854-A05CB18F-4017-404C-8353-6EFE4545A917Q36499731-C8563555-B728-40F1-A06F-D0FE5D5F27E9Q36595020-32DC21F0-0B1E-45DD-A271-BF01C9DCA39AQ36600664-2D3D390C-73B4-4735-88B8-710FC8AFA481Q36668062-C8015A93-F228-4827-B026-3CBB62D552F7Q36853970-013DE2CF-3C11-4497-AFD1-8F741EBD96DCQ36914029-AF99BAB7-AFBC-4CD1-B772-B54506AB081C
P2860
The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@en
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@nl
type
label
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@en
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@nl
prefLabel
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@en
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@nl
P2093
P1476
The alpha-2 adrenergic agonist ...... for alpha-2 receptor subtypes.
@en
P2093
A F Arnsten
P S Goldman-Rakic
P304
P356
10.1523/JNEUROSCI.08-11-04287.1988
P407
P577
1988-11-01T00:00:00Z